華大基因(300676.SZ)業績快報:2020年淨利升652.78%至20.8億元
格隆匯2月26日丨華大基因(300676.SZ)披露2020年度業績快報,報吿期內,公司預計實現營業收入84.32億元,同比增長201.09%;預計營業利潤為24.98億元,同比增長656.60%;預計利潤總額為24.44億元,同比增長644.71%;預計歸屬於上市公司股東的淨利潤為20.8億元,同比增長652.78%;基本每股收益5.2301元。
報吿期內公司業績保持強勁的增長,主要是因為全球範圍內受新型冠狀病毒肺炎疫情影響,市場對新冠病毒檢測試劑盒及檢測服務的需求增加,新冠病毒檢測試劑盒銷售與“火眼”實驗室“雙線佈局”成果顯著,促使公司2020年度整體銷售規模及業績呈現大幅增長。同時公司持續進行研發投入,深化國際和國內市場的拓展,積極進行各項產品推廣,營業收入和淨利潤均持續穩定增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.